PT - JOURNAL ARTICLE AU - Wang, Zhongxin AU - shang, Jian AU - Zhang, Guannan AU - Kong, Lingjun AU - Zhang, Feng AU - Guo, Ye AU - Dou, Yaling AU - Lin, Jun TI - Evaluating the clinical performance of a novel dual-target stool DNA test for colorectal cancer detection AID - 10.1101/2021.03.10.21252951 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.10.21252951 4099 - http://medrxiv.org/content/early/2021/03/24/2021.03.10.21252951.short 4100 - http://medrxiv.org/content/early/2021/03/24/2021.03.10.21252951.full AB - BACKGROUND AND AIMS Methylation-based stool DNA test showed a promising application for colorectal cancer (CRC) detection. This study aimed to evaluate the performance of a novel dual-target stool DNA test (DT-sDNA), composed of SDC2 and TFPI2, for the detection of CRC in clinical practice by using large-scale data from a multicenter clinical trial.METHODS We enrolled 1,164 participants from three independent hospitals, including 320 CRC patients, 148 adenomas, 396 interfering diseases and 300 healthy controls. Their stool samples were collected and tested paralleled by DT-sDNA test under the guidance of standard operating procedure. All participants were dichotomized as positive and negative according to the cycling threshold (Ct) values measured by quantitative methylation-specific PCR (MSP). The diagnostic performance of DT-sDNA test was assessed by calculating indexes of sensitivity, specificity, and overall coincidence rate. Sanger sequencing and retesting of resected participants were performed to verify the accuracy and effectiveness of the test.RESULTS Overall, the sensitivity, specificity, and total coincidence rate of DT-sDNA test for CRC detection were 95.31%, 88.39%, and 90.29%, respectively, with the kappa value of 0.775 (P < 0.05) when comparing to non-CRCs. The sensitivities for the detection of advanced adenomas (n=38) and non-advanced adenomas (n=110) were 63.16% and 33.64%, and the specificity was 96.67% for healthy normal controls. The methylation status of SDC2 and TFPI2 in 375 samples were verified by Sanger sequencing and the average coincidence rate reached 99.62%. The coincidence rate was 94.12% (n=32) for 34 participants that undertook DT-sDNA test again after surgical resection. These results demonstrated high accuracy of the DT-sDNA test in discriminating CRCs from other diseases and healthy controls.CONCLUSIONS The novel DT-sDNA test showed good performance for the diagnosis of colorectal cancer in clinical practice; fda.hubei.gov.cn number; 20190020787.Competing Interest StatementYL Dou reports research funding from Wuhan Ammunition Life-tech Company, Ltd., Hubei, China. LL Zhang, LL Dong, CM Lu, and KK Wan are the employees of Wuhan Ammunition Life-tech Company, Ltd. All other authors declare no conflict of interest.Clinical Trialhttp://fda.hubei.gov.cn/bsfw/bmcxfw/bjcx/Funding StatementYL Dou reports research funding from Wuhan Ammunition Life-tech Company, Ltd., Hubei, China.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was performed parallelly in three centers after it was approved by the institutional ethics review committee of each hospital. The approved ID numbers of Peking Union Medical College Hospital, The First Affiliated Hospital of Anhui Medical University, and Zhongnan Hospital of Wuhan University were KS2020260, PJ2019-09-04, and 2019009-1K, respectively. All participants signed informed consent and were told the test results.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll necessary data used in this study are presented in the manuscript and supplementary materials. The raw data are available from the corresponding author on reasonable request.